pI: 4.6969 |
Length (AA): 138 |
MW (Da): 15885 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_130150)
Species | Accession | Gene Product |
---|---|---|
Drosophila melanogaster | Dmel_CG15143 | CG15143 gene product from transcript CG15143-RA |
Drosophila melanogaster | Dmel_CG15145 | CG15145 gene product from transcript CG15145-RA |
Drosophila melanogaster | Dmel_CG15144 | CG15144 gene product from transcript CG15144-RB |
Echinococcus granulosus | EgrG_000095200 | AMY 1 associating protein expressed in testis |
Echinococcus multilocularis | EmuJ_000278200 | hypothetical protein |
Echinococcus multilocularis | EmuJ_000095200 | AMY 1 associating protein expressed in testis |
Giardia lamblia | GL50803_89828 | Hypothetical protein |
Homo sapiens | ENSG00000183833 | MYCBP-associated, testis expressed 1 |
Leishmania braziliensis | LbrM.33.2510 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_332350.1 | Solute carrier (proton/amino acid symporter), TRAMD3 or PAT1, putative |
Leishmania infantum | LinJ.33.2350 | hypothetical protein, conserved |
Leishmania major | LmjF.33.2220 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.32.2220 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000022805 | MYCBP-associated, testis expressed 1 |
Neospora caninum | NCLIV_009010 | hypothetical protein, conserved |
Plasmodium berghei | PBANKA_1420700 | MAATS1 domain-containing protein, putative |
Plasmodium falciparum | PF3D7_0714100 | MAATS1 domain-containing protein, putative |
Plasmodium knowlesi | PKNH_1423000 | MAATS1 domain-containing protein, putative |
Plasmodium vivax | PVX_122935 | hypothetical protein, conserved |
Plasmodium yoelii | PY02617 | hypothetical protein |
Schistosoma japonicum | Sjp_0103480 | AMY-1-associating protein expressed in testis 1, putative |
Schistosoma japonicum | Sjp_0078000 | AMY-1-associating protein expressed in testis 1, putative |
Schistosoma mansoni | Smp_084650 | hypothetical protein |
Schistosoma mansoni | Smp_168020 | hypothetical protein |
Schistosoma mansoni | Smp_168010 | hypothetical protein |
Schmidtea mediterranea | mk4.012243.00 | |
Schmidtea mediterranea | mk4.007906.04 | |
Schmidtea mediterranea | mk4.000946.06 | |
Trypanosoma brucei gambiense | Tbg972.11.3090 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.11.2790 | Solute carrier (proton/amino acid symporter), TRAMD3 or PAT1, putative |
Trypanosoma congolense | TcIL3000_0_14790 | Solute carrier (proton/amino acid symporter), TRAMD3 or PAT1, putative |
Trypanosoma congolense | TcIL3000.11.2530 | hypothetical protein, conserved |
Trypanosoma cruzi | TcCLB.506303.130 | Solute carrier (proton/amino acid symporter), TRAMD3 or PAT1, putative |
Trypanosoma cruzi | TcCLB.506811.100 | Solute carrier (proton/amino acid symporter), TRAMD3 or PAT1, putative |
Toxoplasma gondii | TGME49_254750 | c3orf15 protein |
Trichomonas vaginalis | TVAG_140020 | conserved hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.02.0354 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb11.02.0354 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.02.0354 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.02.0354 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_254750 | Toxoplasma gondii | Probably non-essential | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.